Why the study?
Recent data highlight a need to increase non-statin lipid-lowering approaches to reduce cardiovascular burden in patients at highest risk beyond statin utilization.
This review highlights the emerging role of novel non-statin lipid-lowering therapies in addressing residual cardiovascular risk among high-risk patients.
Residual risk persists despite statins; leaves open optimal use of novel non-statin therapies pending RCTs.
Purpose of review Based on the recent data of the DA VINCI study, it is clear that, besides utilization of statins, there is a need to increase non-statin lipid lowering approaches to reduce the cardiovascular burden in patients at highest risk. Recent findings For hypercholesterolemia, the small synthetic molecule bempedoic acid has the added benefit of selective liver activation, whereas inclisiran, a hepatic inhibitor of the PCSK9 synthesis, has comparable effects with PCSK9 monoclonal antibodies. For hypertriglyceridemia, cardiovascular benefit has been achieved by the use of icosapent ethyl, whereas results with pemafibrate, a selective agonist of PPAR-α, are eagerly awaited. In the era of RNA-based therapies, new options are offered to dramatically reduce levels of lipoprotein(a) (APO(a)L RX ) and of triglycerides (ANGPTL3L RX and APOCIII-L Rx ). Summary Despite the demonstrated benefits of statins, a large number of patients still remain at significant risk because of inadequate LDL-C reduction or elevated blood triglyceride-rich lipoproteins or lipoprotein(a). The area of lipid modulating agents is still ripe with ideas and major novelties are to be awaited in the next few years.
No takes yet. Share an insight, caveat, or question.
Ruscica et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: